Aktis Oncology Inc AKTS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-01-09 |
| Shares Out. | 53,400,000 |
| Website | aktisoncology.com/ ↗ |
| Phone | 13026587581 |
| Employees | 79 |
| Revenue | $3.2M |
| Gross Profit | $3.2M |
| Net Income | -$18.3M |
| Total Assets | $576.8M |
| Total Liabilities | $70.7M |
| Equity | $506.1M |
About Aktis Oncology Inc
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Aktis Oncology Inc is a publicly traded company under the ticker symbol AKTS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)